Skip to main content
Premium Trial:

Request an Annual Quote

Lucira Health SARS-CoV-2 Self-Test Receives Health Canada Conditional Authorization

NEW YORK – Lucira Health announced on Monday that the Lucira Check It COVID-19 test kit received an Authorization with Conditions from Health Canada.

The authorization was granted under Health Canada's Interim Order, which allows COVID-19 products that might not fully meet Canadian regulatory requirements to be imported and sold if they're manufactured to comparable standards.

The loop-mediated isothermal amplification test can deliver results in 30 minutes or less and will be available for Canadians to buy online in June for around C$75 (US$60), the company said in a statement. Lucira added that its kit is the first self-test authorized by Health Canada for people with or without symptoms.

Lucira's test can determine a positive result within 11 minutes or confirm a negative result within 30 minutes and doesn't require a prescription or supervised assistance to perform. Earlier this month, the test received Emergency Use Authorization from the US Food and Drug Administration for over-the-counter use at home. It previously received a separate EUA in November for prescription use under the name Lucira COVID-19 All-In-One Test Kit.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.